U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07873671) titled 'A Trial of RLX-2508-102 in Healthy Volunteers' on Oct. 08.
Brief Summary: The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.
Study Start Date: Nov. 15
Study Type: INTERVENTIONAL
Condition:
Influenza
Intervention:
DRUG: RLX-2508
Single dose RLX-2508 /placebo given subcutaneously - Dose level 1
DRUG: RLX-2508
Single dose RLX-2508 /placebo given subcutaneously - Dose level 2
DRUG: RLX-2508
Repeated dose of RLX-2508 /placebo given subcutaneously - Dose level 3
DRUG: RLX-2508
Single dose of RL...